Bernstein downgraded Eurofins stock to Market Perform

Published on 10/08/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eurofins stock costs EUR 76.38 on October 8, 2026 versus EUR 76.56, minus 0.24 percent. First-half earnings per share grew 29.00 percent.

3D-Architekturvisualisierung eines gläsernen Forschungs- und Bürokomplexes mit Wasserbecken — Architektur-Render eines modernen Forschungscampus visualisiert die Infrastruktur von Eurofins Scientific SE, ISIN FR0014000MR3, unbeschriftet, Illustration mit AI erstellt.

Eurofins Scientific SE (FR0014000MR3) was trading at EUR 76.38 at Lang & Schwarz on October 8, 2026 at 11:33 a.m. CEST, down 0.24 percent versus the prior close of EUR 76.56. Markets Insider reported that Bernstein downgraded Eurofins from Outperform to Market Perform on September 29, 2026, with a EUR 73.90 price target.

Bernstein highlights weaker growth

The downgrade places the current Lang & Schwarz price above Bernstein's target, making the analyst view a direct valuation counterweight to the recent share price level. The target is EUR 2.48 below the latest euro quote, while the analyst action came after an earlier period of stronger operating momentum.

Bernstein's note also described Eurofins' biopharma organic growth outlook as subdued, according to Markets Insider. For investors, that assessment matters because the group has been using acquisitions to reinforce its laboratory network while seeking margin expansion.

Half-year earnings improved margins

Eurofins said its first-half 2026 results, published on July 23, 2026, showed 29.00 percent growth in earnings per share and a 130 basis point expansion in adjusted EBITDA margin. The combination gives the downgrade a specific test: future results must show whether operating improvement can offset the slower organic-growth concern.

The company also retains a fiscal year 2027 adjusted EBITDA margin objective of 24.00 percent, according to Eurofins. That target is a longer-dated benchmark rather than a new quarter figure, but it frames the margin expansion reported for the first half.

Portfolio moves reshape the group

Eurofins completed the acquisition of Element Materials Technology's North American Life Sciences Testing Services business on October 1, 2026, for an enterprise value of USD 400 million, Business Wire reported. The acquired network includes 27 laboratories and facilities, employs approximately 750 staff, and is expected to generate more than USD 150 million in annual revenue in 2026.

On the same date, Eurofins completed the divestment of its Electrical and Electronic Testing business to UL Solutions for an enterprise value of EUR 575 million, according to Business Wire. The transactions point to a deliberate shift toward life sciences testing and capital allocation priorities such as debt reduction, digital systems and strategic acquisitions.

Eurofins stock stays near its yearly high

Eurofins stock stood at EUR 76.38 at Lang & Schwarz on October 8, 2026 at 11:33 a.m. CEST, compared with a 52-week range of EUR 54.86 to EUR 79.22. The market capitalization was EUR 13.2 billion as of October 8, 2026, leaving the quote EUR 2.84 below the reported 52-week high.

The trading picture therefore combines a modest intraday decline with an analyst target below the current quote, while the company's first-half margin and earnings figures provide a measurable operating counterpoint. The next investor event is scheduled for October 23, 2026, when Eurofins will host an investor event in Amersfoort, Netherlands, according to Eurofins.

Price and investor reference

Eurofins stock was trading at EUR 76.38 at Lang & Schwarz on October 8, 2026 at 11:33 a.m. CEST, down 0.24 percent versus the Lang & Schwarz prior close of EUR 76.56 on October 7, 2026. Its primary listing is on Euronext Paris, where the quotation currency is EUR. The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.